Business Context and Reporting Period
Company: Elutia Inc. (formerly Aziyo Biologics, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Elutia is a commercial-stage medical device company focused on regenerative medicine products to reduce complications associated with implanted medical devices. The company operates in three segments: Device Protection (EluPro, CanGaroo), Women's Health (SimpliDerm), and Cardiovascular (ProxiCor, Tyke, VasCure). In November 2023, the company divested its Orthobiologics Business to Berkeley Biologics, LLC, retaining liabilities related to product recalls.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Net Sales | $24.4 million | $24.7 million |
| Gross Profit | $10.7 million (43.9% margin) | $11.1 million (44.7% margin) |
| Net Loss | $(53.9) million | $(37.7) million |
| Operating Expenses | $46.4 million | $41.6 million |
| Litigation Costs, Net | $11.4 million | $10.0 million |
| Cash and Cash Equivalents | $13.2 million | $19.3 million |
| Total Debt (SWK Loan Facility) | $23.5 million | $23.5 million |
| Accumulated Deficit | $(229.6) million | $(175.6) million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 1.5% to $24.4 million. While Device Protection and Women's Health segments saw growth (driven by EluPro commercialization starting in September 2024), Cardiovascular sales dropped 42.2% due to a shift to a distributor model with LeMaitre Vascular.
- Increased Losses: Net loss widened by 43.3% to $53.9 million. This was driven by a $14.9 million loss on the revaluation of warrant liabilities, increased litigation costs, and higher General and Administrative expenses (up 32.3% due to equity compensation).
- Segment Performance: Device Protection gross margin decreased to 63.7% (from 69.8%) as the mix shifted toward the newer, lower-margin EluPro product. Women's Health gross margin improved to 51.8% (from 42.7%).
- Discontinued Operations: The company recognized a $0.2 million gain in 2024 related to the final working capital adjustment from the 2023 sale of the Orthobiologics Business.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern within one year of the financial statement issuance date. The company has an accumulated deficit of $229.6 million and expects to continue incurring operating losses. Future funding is required to meet obligations, including debt service and litigation costs.
Key Risks and Contingencies
- Product Liability Litigation: The company faces significant litigation related to the FiberCel and Viable Bone Matrix (VBM) recalls (tuberculosis infections).
- FiberCel: 66 active lawsuits. Estimated liability is $15.9 million. Insurance coverage is exhausted; the full liability is the company's financial responsibility.
- VBM: 15 active lawsuits. Estimated liability is $4.5 million. Insurance coverage remains available.
- Total Contingent Liability: $20.4 million recorded on the balance sheet.
- Debt Covenants: The company has a $23.5 million SWK Loan Facility maturing in 2027. It is currently in compliance with financial covenants (minimum revenue and liquidity), but future breaches could trigger immediate repayment.
- Revenue Interest Obligation: The company owes Ligand Pharmaceuticals 5% of future sales of specific products with an annual minimum payment of $4.4 million through May 2027.
- Commercialization of EluPro: Future success is heavily dependent on the commercialization of EluPro (FDA cleared June 2024). The company expects sales and marketing costs to increase in 2025 to support this launch.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $13.2 million cash balance against the $22.7 million operating cash burn and upcoming debt/royalty obligations.
- Insurance Exhaustion: Confirm the status of the FiberCel litigation liability ($15.9 million) and the lack of remaining insurance coverage.
- Debt Covenant Compliance: Monitor quarterly revenue and liquidity metrics to ensure continued compliance with the SWK Loan Facility covenants.
- EluPro Adoption: Track the commercial uptake of EluPro in 2025 to determine if it can offset the loss of Orthobiologics revenue and cover increased operating costs.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $16.1 million warrant liability, which caused a significant non-cash loss in 2024.